 Connection
Mary Sammel to Ovarian Neoplasms
This is a "connection" page, showing publications Mary Sammel has written about Ovarian Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.356 |
|
|
|
-
Shanmugan S, Sammel MD, Loughead J, Ruparel K, Gur RC, Brown TE, Faust J, Domchek S, Epperson CN. Executive function after risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: does current mood and early life adversity matter? Menopause. 2020 07; 27(7):746-755.
Score: 0.103
-
Johnson L, Sammel MD, Domchek S, Schanne A, Prewitt M, Gracia C. Antimüllerian hormone levels are lower in BRCA2 mutation carriers. Fertil Steril. 2017 05; 107(5):1256-1265.e6.
Score: 0.083
-
Chan JL, Johnson LNC, Sammel MD, DiGiovanni L, Voong C, Domchek SM, Gracia CR. Reproductive Decision-Making in Women with BRCA1/2 Mutations. J Genet Couns. 2017 Jun; 26(3):594-603.
Score: 0.080
-
Adams SF, Marsh EB, Elmasri W, Halberstadt S, Vandecker S, Sammel MD, Bradbury AR, Daly M, Karlan B, Rubin SC. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecol Oncol. 2011 Dec; 123(3):486-91.
Score: 0.056
-
Metcalf CA, Page CE, Stocker BOS, Johnson RL, Duffy KA, Sammel MD, Loughead J, Epperson CN. Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine. Gynecol Oncol. 2024 11; 190:62-69.
Score: 0.034
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|